- Associated Press - Wednesday, February 16, 2011

PARIS (AP) - French pharmaceutical company Sanofi-Aventis says it has agreed to buy Genzyme for $74 a share in a deal that values the U.S. biotechnology company at $20.1 billion.

Sanofi-Aventis says in a statement Wednesday that it also agrees to make additional cash payments to Genzyme shareholders contingent on the success of several of the company’s drugs.

Genzyme is based in Cambridge, Massachusetts.

Copyright © 2019 The Washington Times, LLC.

The Washington Times Comment Policy

The Washington Times welcomes your comments on Spot.im, our third-party provider. Please read our Comment Policy before commenting.


Click to Read More and View Comments

Click to Hide